Cargando…
Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11
The emergence of SARS-CoV-2 antibody escape mutations highlights the urgent need for broadly neutralizing therapeutics. We previously identified a human monoclonal antibody, 47D11, capable of cross-neutralizing SARS-CoV-2 and SARS-CoV and protecting against the associated respiratory disease in an a...
Autores principales: | Fedry, Juliette, Hurdiss, Daniel L., Wang, Chunyan, Li, Wentao, Obal, Gonzalo, Drulyte, Ieva, Du, Wenjuan, Howes, Stuart C., van Kuppeveld, Frank J.M., Förster, Friedrich, Bosch, Berend-Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172134/ https://www.ncbi.nlm.nih.gov/pubmed/33958322 http://dx.doi.org/10.1126/sciadv.abf5632 |
Ejemplares similares
-
A human monoclonal antibody blocking SARS-CoV-2 infection
por: Wang, Chunyan, et al.
Publicado: (2020) -
Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection
por: Wang, Chunyan, et al.
Publicado: (2020) -
An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
por: Du, Wenjuan, et al.
Publicado: (2022) -
Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants
por: Du, Wenjuan, et al.
Publicado: (2023) -
Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across mammals
por: Li, Meng, et al.
Publicado: (2023)